TransEnterix, a developer of robotic and flexible instrument technology for use in surgery, has landed a loan worth up to $25 million.

The deal provides “up to three quarters of additional capital to satisfy our operating cash requirements,” says CEO Todd Pope.

TransEnterix (NYSE MKT: TRXC) announced the deal with Oxford Finance and Silicon Valley Bank early Tuesday.

The two firms have worked with TransEnterix before.

Terms call for TransEntrix to receive the funding in three tranches.

The company executed a reverse stock split, raised some $50 million and move to a new stock exchange earlier this year.